Jean-Yves Pierga, MD, PhD, Institut Curie, Paris, France, comments on the role of trastuzumab deruxtecan in settings other than pre-treated HER2+ breast cancer. In addition to the DESTINY-Breast03 trial (NCT03529110), which compares the antibody-drug conjugate (ADC) with trastuzumab emtansine, the DESTINY-Breast06 trial (NCT04494425), will assess trastuzumab deruxtecan in HER2-low/HR+ breast cancer. The DESTINY-Breast09 trial (NCT04784715) also investigates trastuzumab deruxtecan with or without pertuzumab in the first line setting. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
